newsfilter

$VRUS News

Last published 5y ago

  • 5y agoVRUSVerus International Signs 3rd U.S. Distributor – Provides CEO UpdateGlobeNewswireGaithersburg, MD, July 12, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. ("Verus" or the "Company") (OTC:VRUS), an international food, CBD and hemp-based products company, is pleased to announce that it has signed its 3rd U.S. distributor for its
  • 5y agoVRUSVerus International Reports Fiscal 2021 Q2 Financial Results; Posts Significant Improvement in Gross Profit MarginsGlobeNewswireGaithersburg, MD, June 22, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. ("Verus" or the "Company") (OTC:VRUS), an international food, CBD and hemp-based products company, reported financial results for the fiscal 2021 second quarter, which ended
  • 5y agoVRUSVerus International Provides Corporate UpdateGlobeNewswireGaithersburg, MD, May 21, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. ("Verus" or the "Company") (OTC:VRUS), an international food, CBD and hemp-based products company, today is providing a corporate update to inform investors of business trends
  • 5y agoVRUSVerus International Releases CEO Corporate Update LetterGlobeNewswireGaithersburg, MD, April 29, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. ("Verus" or the "Company") (OTC:VRUS), an international food, CBD and hemp-based products company, today released a corporate update letter from its CEO Andy Dhruv. Val
  • 5y agoVRUSVerus International Adds Second Distributor for New Hemp-Based Waffles LineGlobeNewswireGaithersburg, MD, April 22, 2021 (GLOBE NEWSWIRE) -- Verus International, Inc. ("Verus" or the "Company") (OTC:VRUS) is pleased to report that it has signed a second distributor for its new hemp-based Waffles product line. The new distributor will begi
  • 14y agoMWIVCCGZINCVRUSCorporate Leaders Receive Twelfth Annual Emerald Asset Management “E-3 Awards”Business WirePHILADELPHIA--(BUSINESS WIRE)--The Chief Executive Officers of MWI Veterinary Supply, Inc. (NASDAQ: MWIV) and Campus Crest Communities, Inc. (NYSE: CCG) and the Chief Financial Officer of Horsehead Holding Corp. (NASDAQ: ZINC) are among the corporate executives named as the recipients of the twelfth annual “E-3 Awards,” presented by Emerald Asset Management at the Nineteenth Annual Emerald Groundh ...
  • 14y agoGILDVRUSGilead Sciences Completes Acquisition of Pharmasset, Inc.Business WireFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Royal Merger Sub II Inc., a wholly-owned subsidiary of Gilead (“Merger Sub II”), to acquire Pharmasset, Inc. (Nasdaq: VRUS) for $137 per share in cash, or approximately $11.2 billion in the aggregate.
  • 14y agoGILDVRUSGilead Sciences Completes Tender Offer for All Outstanding Shares of Pharmasset, Inc.Business WireFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Royal Merger Sub II Inc. (“Merger Sub II”), for all of the outstanding shares of common stock of Pharmasset, Inc. (Nasdaq:VRUS) at a price of $137 per share, net to the seller in cash (less any required withholding taxes and without ...
  • 14y agoGILDVRUSGilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting PeriodBusiness WireFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has received early termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead’s cash tender offer for Pharmasset, Inc (Nasdaq: VRUS).
  • 14y agoGILDVRUSGilead Sciences to Acquire Pharmasset, Inc. for $11 BillionBusiness WireFOSTER CITY, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Pharmasset, Inc. (Nasdaq:VRUS) announced today that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction, which values Pharmasset at approximately $11 billion, was unanimously approved by Pharmasset’s Board of Directors. ...
  • 15y agoVRUSBMYNew 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1Business WirePRINCETON, N.J.--(BUSINESS WIRE)--Pharmasset, Inc. (Nasdaq: VRUS) and Bristol-Myers Squibb Company (NYSE: BMY) announced today the addition of four treatment arms to the ongoing Phase IIa trial evaluating the combination of Pharmasset’s PSI-7977, a nucleotide polymerase inhibitor, and Bristol-Myers Squibb Company’s (NYSE: BMY) daclatasvir (BMS-790052), an investigational NS5A replication complex i ...
  • 15y agoWTRBNCLBRLIBIOS+14Emerald Holds Annual Groundhog Day Investment ForumBusiness WireLANCASTER, Pa.--(BUSINESS WIRE)--Emerald Asset Management will hold it’s Eighteenth Annual Emerald Groundhog Day Investment Forum on Wednesday, February 2, 2011 at the Radisson Plaza-Warwick Hotel in Philadelphia. “Energy and passion are hallmarks of the Emerald Groundhog Day Investment Forum,” said Emerald Founder and CEO, Joseph E. Besecker. “The Forum provides a venue to discuss key challenges ...